# Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

> **NCT00006033** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** gene therapy
- **BIOLOGICAL:** interleukin-2 gene
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00006033
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006033, "Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00006033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*